Cancer Chemotherapy and Selective Drug Development: Proceedings of the 10th Anniversary Meeting of the Coordinating Committee for Human Tumour Investigations, Brighton, England, October 24–28, 1983Over the past 30 years many significant advances have been made in the management of a number of disseminated malignant diseases. The prognosis for diseases such as childhood leukaemia, choriocarcinoma and Hodgkin's disease has gradually been transformed as better anti tumour agents have become available and their clinical use has been refined. During the past 10 years the advent of new agents, particularly cisplatin, bleomycin and the podophyllotoxins, has allowed the cure of disseminated testicular tumours. This degree of success has not, however, been achieved in the case of a number of other common cancers. Ovarian carcinoma is tantalisingly chemo-sensitive and although there are long term survivors from disseminated disease, these are only a small proportion of the total. Breast cancer, although "sensitive" to a multitude of drugs appears to have yielded neither survival benefit, nor cure to the efforts of therapists, while tumours such as those of the colon remain stubbornly unresponsive. Against this backcloth it is apparent that additional more selective treatments are needed if further impact is to be made on the problem of cancer. The development of such agents requires the integration of a multidisciplinary effort encompassing the fields of chemistry, biology and medicine. This symposium provided a forum for clinical and preclinical sCientists, where current aspects of cancer treatment were reviewed and approaches to the development of a new generation of more selective anticancer drugs discussed. |
Contents
5 | |
New therapies with old drugs | 13 |
Mismatched bone marrow transplantation | 33 |
Prospects for immunotherapy | 43 |
A promising new agent for the treatment of human | 55 |
Current clinical progress podophyllotoxins | 65 |
alkylating agents | 77 |
Interferon | 83 |
Antibodytoxin conjugates as anticancer agents | 263 |
Biological response modifiers as anticancer agents | 271 |
Prostaglandins and cancer therapeutic potential | 277 |
The interleukins | 289 |
Polyamines immune response and tumour growth control | 301 |
Inosine 5phosphate dehydrogenase as a target for cancer | 315 |
Antitumour activity and pharmacology of CCRG 81010 | 321 |
Lipophilic inhibitors of dihydrofolate reductase | 333 |
Chemotherapy of lung cancer | 91 |
Chemotherapy of ovarian cancer | 105 |
Treatment of disseminated malignant lymphoma | 117 |
Malignant disease in childhood | 123 |
Chemotherapy of disseminated testicular cancer | 135 |
Effective use of narcotic analgesics | 147 |
Nonnarcotics and coanalgesics | 159 |
Why do cancer patients vomit? | 173 |
The medical management of malignant bowel obstruction | 183 |
Etiology of chemotherapyinduced vomiting | 189 |
The management of nausea and vomiting caused by anticancer | 195 |
Experimental models and their predictive value in new drug | 209 |
In vivo antitumour models and drug development | 215 |
Mechanisms of resistance to anticancer agents | 227 |
Novel structures in development | 235 |
Induction of cell differentiation as a target for cancer therapy | 251 |
New developments in anthracyclines | 345 |
Further objectives in the development of platinum drugs | 357 |
The structure of active genes and HMG proteins in normal | 365 |
Structural requirements for DNA intercalation and their | 377 |
DNA repair characteristics of Walker rat carcinoma cells | 389 |
Is alkylating agent priming a DNA repair phenomenon? | 395 |
DTIC induces damage in melanoma DNA during semiconservative | 401 |
Alkylating antitumour agents decrease histone acetylation | 413 |
Cytotoxicity of a steroidlinked mustard Estramustine through | 425 |
Adjuvant tamoxifen treatment in operable breast cancer Should | 439 |
Adjuvant hormonal therapy of breast cancer | 445 |
The pharmacology of a new antiestrogen | 457 |
Tissue distribution and myelotoxicity of daunomycin in normal | 546 |
583 | |
Other editions - View all
Cancer Chemotherapy and Selective Drug Development: Proceedings of the 10th ... K.R. Harrap,W. Davis,A.H. Calvert No preview available - 2011 |
Cancer Chemotherapy and Selective Drug Development K R Harrap,W Davis,A H Calvert No preview available - 1984 |
Common terms and phrases
acid adjuvant adriamycin advanced breast cancer alkylating agents aminoglutethimide analgesic analogue antibody anticancer antiemetic antiestrogens antigen antitumour activity assay binding Biochem biological bone marrow breast cancer cancer chemotherapy Cancer Res Cancer Research Cancer Treat carcinoma cell lines chemotherapy chlorambucil chromatin cisplatin clinical trials combination chemotherapy compounds concentrations crosslinking cyclophosphamide cytosol cytotoxic differentiation disease drug DTIC effect endocrine enzyme estradiol estramustine evaluation experimental fluorouracil growth histone hormone Hospital human tumour increase incubation induced inhibition inhibitors interferon interstrand leukaemia levels lymphocytes lymphokines lymphoma malignant mammary matrix melanoma melphalan metabolism metastases methotrexate mg/Mē mice misonidazole mitoxantrone MNNG monoclonal murine nitrosoureas normal nuclear nuclei nucleosomes Oncology ovarian pain patients pharmacokinetics Pharmacol phase plasma platinum polyamines potential Proc prostate proteins remission renal resistance response rate sensitive serum shown studies survival synthesis Table tamoxifen therapeutic therapy thymidine tissue toxicity transplantation treatment tumour tumour cells vitro vivo xenografts